Supported by several international scientific studies, the benefits of the bioactive collagen peptides FORTIGEL for the joints of the human body now have functional claim approval in Brazil. The National Health Agency (Anvisa) authorized the claim with the wording “may contribute to the maintenance of joint health” on the labels of food supplements formulated with the ingredient patented by GELITA, a leader in the manufacture and supply of gelatin and collagen. The decision was published on September 26 in DOU (Diário Oficial da União), considering the dosage of 5g a day.
“FORTIGEL is the first type I collagen to receive this joint approval. Supported by several studies carried out by the international scientific community, proving its effectiveness, and confirming the premise that not all collagens are the same. It is gratifying that the functional effectiveness of our solution dedicated to joint health received this important approval from the regulatory agency in the Brazilian market”, says Léia Tomaz Pipulini, head of the Nutrition & Health Ingredients business unit at GELITA South America.
